Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma

LONDON, December 30, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), ImmunoGen Inc. (NASDAQ: IMGN), Exelixis Inc. (NASDAQ: EXEL), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, December 29, 2014, ended flat as the Dow Jones Industrial Average finished at 18,038.23, down 0.09% and the NASDAQ Composite ended at previous day's closing of 4,806.91. The S&P 500 finished the session 0.09% higher at 2,090.57. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 803.07, up 0.26%, with the index advancing 7.88% in the previous three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

Gilead Sciences Inc.'s stock gained 3.74%, to close the day at $97.30. The stock recorded a trading volume of 20.51 million shares, above its three months average volume of 16.87 million shares. The company's shares oscillated between $95.40 and $97.42 during the session. Over the last one month and over the past three months, Gilead Sciences Inc.'s shares have lost 3.01% and 9.50%, respectively. However, the stock has surged 8.78% in the previous three trading sessions and 29.56% since the start of this year. The company is trading above its 200-day moving average of $91.92, while the 200-day moving average is below Gilead Sciences Inc.'s 50-day moving average of $103.86. Additionally, the stock traded at a PE ratio of 17.20 and has a Relative Strength Index (RSI) of 39.31. Sign up and read the free notes on GILD at:

http://get.Investor-Edge.com/pdf/?c=Gilead%20Sciences&d=30-Dec-2014&s=GILD

On Monday, shares in ImmunoGen Inc. recorded a trading volume of 2.49 million shares, higher than its three months average volume of 1.67 million shares. The stock ended the day at $6.26, which was 5.56% above its previous day's closing of $5.93, and registered an intraday range of $5.97 and $6.33. ImmunoGen Inc.'s shares have surged 8.49% in the previous three trading sessions, while the stock has plummeted 39.16% in the last one month and 57.33% on YTD basis. The company is trading below its 50-day and 200-day moving averages of $9.24 and $11.34, respectively. Furthermore, shares of ImmunoGen Inc. have an RSI of 28.88. The complimentary notes on IMGN can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=ImmunoGen&d=30-Dec-2014&s=IMGN

Exelixis Inc.'s stock advanced 1.50% to end Monday's session at $1.35. The stock recorded a trading volume of 2.78 million shares, above its three months average volume of 2.69 million shares. The company's shares fluctuated between $1.30 and $1.36 during the session. Exelixis Inc.'s shares have plummeted 18.67% over the last one month and 77.98% since the beginning of 2014. However, the stock has gained 3.85% in the previous three trading sessions. The company is trading below its 50-day and 200-day moving averages. Exelixis Inc.'s 200-day moving average of $2.92 is above its 50-day moving average of $1.58. Additionally, the stock has an RSI of 38.12. Register for free on Investor-Edge and access the latest research on EXEL at:

http://get.Investor-Edge.com/pdf/?c=Exelixis&d=30-Dec-2014&s=EXEL

On Monday, shares in Cubist Pharmaceuticals Inc. fluctuated between $100.30 and $100.80 before ending the session 0.41% higher at $100.71. The stock reported a trading volume of 1.55 million shares, lower than its three months average volume of 2.07 million shares. Shares of the company traded at a PE ratio of 115.27. Cubist Pharmaceuticals Inc.'s stock has rallied 32.85% in the last one month, 51.47% in the previous three months, and 46.23% on YTD basis. The company is trading above its 50-day and 200-day moving averages of $79.40 and $70.30, respectively. Moreover, shares of Cubist Pharmaceuticals Inc. have an RSI of 79.08. The complete research on CBST is available for free at:

http://get.Investor-Edge.com/pdf/?c=Cubist%20Pharma&d=30-Dec-2014&s=CBST

Vanda Pharmaceuticals Inc.'s stock finished Monday's session 1.20% lower at $14.83. A total of 0.42 million shares were traded, which was below its three months average volume of 0.76 million shares. The stock vacillated between $14.56 and $15.25 during the session. Over the last one month and over the past three months, Vanda Pharmaceuticals Inc.'s shares have surged 13.81% and 40.30%, respectively. Additionally, from the beginning of 2014, the stock has gained an upside of 19.50%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $13.00 is greater than its 50-day moving average of $12.17. Vanda Pharmaceuticals Inc.'s stock has an RSI of 70.29. Free in depth research on VNDA is available at:

http://get.Investor-Edge.com/pdf/?c=Vanda%20Pharma&d=30-Dec-2014&s=VNDA

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED